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ABSTRACT 
BACKGROUND AND PURPOSE 
H2S protects myocardium against ischaemia-reperfusion injury. This protection may involve 
the cytosolic reperfusion injury salvage kinase (RISK) pathway, but direct effects on 
mitochondrial function are possible. Here, we investigated the potential cardioprotective 
effect of mitochondria-specific H2S donor, AP39, at reperfusion against 
ischaemia/reperfusion injury. 
 
EXPERIMENTAL APPROACH 
Anaesthetised rats underwent myocardial (30 min ischaemia/120 min reperfusion) with 
randomisation to receive interventions prior to reperfusion: vehicle, AP39 (0.01, 0.1, 1 µmol 
kg-1), or the control compounds AP219 or ADT-OH (1 µmol kg-1). LY294002, L-NAME or 
ODQ were used to interrogate the involvement of RISK pathway. Myocardial samples 
harvested 5 minutes after reperfusion were analysed for RISK protein phosphorylation and 
additional experiments were conducted on isolated cardiac mitochondria to examine the 
direct mitochondrial effects of AP39. 
 
KEY RESULTS 
AP39 exerted dose-dependent infarct size limitation. Inhibition of either PI3K/Akt, eNOS or 
sGC did not affect the infarct limitation of AP39. Western blot analysis confirmed that AP39 
did not induce phosphorylation of Akt, eNOS, GSK-3β or ERK1/2. In isolated 
subsarcolemmal and interfibrillar mitochondria, AP39 significantly attenuated mitochondrial 
ROS generation without affecting respiratory complexes I or II. Further, AP39 inhibited 
mitochondrial permeability transition pore (PTP) opening and co-incubation of mitochondria 
with AP39 and cyclosporine A induced an additive inhibition of PTP. 
 
CONCLUSION AND IMPLICATIONS 
AP39 protects against reperfusion injury independently of the cytosolic RISK pathway. 
Cardioprotection could be mediated by inhibiting PTP via cyclophilin D-independent 
mechanism. Thus, selective delivery of H2S to mitochondria may be therapeutically 
applicable for harnessing the cardioprotective utility of H2S. 
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Abbreviations 
RISK, reperfusion injury salvage kinase; AP39, (10-oxo-10-(4-(3-thioxo-3H-1, 2-dithiol-5-
yl)phenoxy)decyl) triphenylphosphonium bromide); AP219, mitochondria-targeting moiety; 
ADT-OH, hydrogen sulfide releasing moiety; eNOS, endothelial nitric oxide synthase; GSK-
3β, glucogen synthase kinase-3beta; PTP, permeability transition pore; H2S, hydrogen sulfide 
 
List of non-approved abbreviations  
3-MST = 3-mercaptopyruvate sulphurtransferase 
AAR = area at risk 
ADT-OH = 5-(4-hydroxyphenyl)-3H-1, 2-dithiole-3-thione 
AP39 = 10-oxo-10-(4-(3-thioxo-3H-1,2-dithiol-5yl)phenoxy)decyl) triphenylphosphonium 
bromide], mitochondria-targeting H2S donor 
CBS = cystathionine beta synthase 
CsA = cyclosporine A 
CSE = cystathionine gamma lyase 
DATS = diallyltrisulfide 
eNOS = endothelial nitric oxide synthase 
GSK-3β = glycogen synthase kinase-3 Beta 
H2S = hydrogen sulfide 
IFM = interfibrillar mitochondria 
IPost-C = ischemic postconditioning 
Mito-ROS: mitochondrial reactive oxygen generation 
NO = nitric oxide 
PBS = phosphate buffered saline 
PostC-H2S = postconditioning with H2S 
PTP = permeability transition pore 
RISK = reperfusion injury salvage kinase (signalling pathway) 
RNS = reactive nitrogen species 
SSM = subsarcolemmal mitochondria 
TPP+= triphenylphosphonium  
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Tables of Links 
Targets Ligands 
Enzymesa AP39 
PI3K AP219 
Akt (PKB) ADT-OH 
eNOS LY294002 
sGC L-NAME 
GSK-3β ODQ 
ERK1 Cyclosporine A 
ERK2 Rhodamine 123 
Cyclophilin D  
 
These tablets list key targets in this article which are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Southan et al., 2016) and are permanently archived in The 
Concise Guide to PHARMACOLOGY 2015/16 (aAlexander et al., 2015).  
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Introduction  
In myocardial ischaemia-reperfusion injury, rapid pH normalisation, Ca2+ overload and 
overwhelming generation of reactive oxygen species (ROS) and reactive nitrogen species 
(RNS) at reperfusion disturb mitochondrial function and result in the opening of the 
mitochondrial permeability transition pore (PTP) (Hausenloy and Yellon, 2007). PTP 
opening leads to collapse of mitochondrial membrane potential, swelling of the mitochondria 
and the leakage of cytochrome c into the cytoplasm. As a result, ATP-production will be 
impaired, initiating cell apoptosis/necrosis (Pell et al., 2016, Murphy et al., 2016). PTP 
opening at reperfusion is believed to be the no-return point of reperfusion injury (Hausenloy 
et al., 2009). Therapeutic targeting of these processes during the first minutes of reperfusion 
has been investigated intensively in experimental settings as early reperfusion appears to 
afford a window of opportunity to prevent PTP opening and ultimately reduce lethal cell 
injury (Ferdinandy et al., 2014). 
 
The roles of endogenous hydrogen sulfide (H2S), in a wide range of physiological systems, 
has been extensively explored following the discovery that it is produced by several regulated 
biochemical pathways in mammalian species (Kimura, 2011). In myocardium, enhanced 
levels of H2S, whether by H2S supplement or increased endogenous production, have been 
shown to protect the heart against ischaemia-reperfusion injury (Johansen et al., 2006, Elrod 
et al., 2007, Karwi et al., 2016). The exact cardioprotective mechanism of H2S yet to be 
clarified but a number of molecular targets have been identified. These include activation of 
the reperfusion injury salvage kinase (RISK) pathway (Hausenloy, 2013); enhanced cellular 
and mitochondrial antioxidant defences; and preservation of mitochondrial integrity (Bos et 
al., 2015). However, these effects have been inconsistent in many experimental studies for 
several reasons including variations in animal species and models, different experimental 
conditions, and inconsistencies in dosing with inorganic sulfide salts (Bos et al., 2015). 
Inorganic sulfide salts (notably NaHS and Na2S) have been extensively employed to explore 
the biological activity of H2S. Nevertheless, these salts are impure and generate H2S 
instantaneously at high (i.e. supraphysiological) concentrations and there is increasing 
concern that they are unreliable sources of H2S (Whiteman et al., 2011). 
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We have examined cardioprotection by a novel mitochondria-targeting H2S donor, AP39 (10-
oxo-10-(4-(3-thioxo-3H-1,2-dithiol-5yl)phenoxy)decyl) triphenylphosphonium bromide) (Le 
Trionnaire et al., 2014) when given as adjunct to reperfusion and its direct effect on 
cardiomyocyte mitochondria, namely, subsarcolemmal and interfibrillar mitochondria. The 
rationale for targeted delivery of H2S to the mitochondria is based on the evidence that H2S 
can attenuate mitochondrial ROS (mito-ROS) generation and preserves mitochondrial 
integrity. There are recent observations that AP39 can successfully deliver H2S into the 
mitochondria when given at reperfusion and that the agent reproducibly protects the 
mitochondria in particular and the cell in general against ischaemia-reperfusion insults in the 
brain and kidney (Ikeda et al., 2015, Ahmad et al., 2016). We hypothesised that AP39 
protects the heart against ischaemia-reperfusion injury when administrated at reperfusion 
though a cytosolic-independent mechanism. We also hypothesised that AP39 attenuates mito-
ROS generation and thereby inhibits PTP opening in the SSM and IFM. 
 
Materials 
AP39 and the control compounds, AP219 and ADT-OH, were synthesised by us as 
previously reported (Tomasova et al., 2014, Szczesny et al., 2014, Le Trionnaire et al., 2014). 
The purity of the compound was determined by NMR spectroscopy (1H, 31P and 13C). The 
irreversible heme-site soluble guanylyl cyclase (sGC) inhibitor 1H-[1,2,4]oxadiazolo[4,3-
a]quinoxalin-1-one (ODQ), the constitutive nitric oxide synthase (NOS) inhibitor L-
nitroarginine methyl ester (L-NAME), the phosphatidylinositol-3-kinase (PI3K) inhibitor 
LY294002, thiobutabarbital sodium salt hydrate (Inactin® hydrate), Evans blue dye, 
triphenyltetrazolium chloride (TTC) and DMSO were all purchased from Sigma-Aldrich, 
Gillingham, UK. Western blotting antibodies were all sourced from Cell Signalling, UK. 
 
Methods 
Animals and ethical statement 
All animals care and procedures for in vivo studies complied with UK Home Office 
Guidelines on the Animals (Scientific Procedures) Act 1986, (published by the Stationery 
Office, London, UK), project licence (PPL30/3032) and was approved by the Animal 
Welfare and Ethical Review Body at Cardiff University. Studies involved mitochondria 
isolation was approved by the Animal Welfare Office of the Justus-Liebig University 
Giessen. Male Sprague Dawley rats, 300-350 g (9-11 weeks), were obtained for in vivo 
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studies from Harlan, UK. For mitochondria isolation, male Wistar rats, 300-350 g (9-11 
weeks), were purchased from Harlan, France. They were housed in polypropylene cages (2-4 
rats in each) on wood shaving litter. Animals acclimatised in the institutional animal house at 
constant temperature and humidity on a 12 hour light/dark cycle for at least seven days prior 
to experimentation, with free access to water and a small animal diet at all times. Animals 
studies were reported in accordance with ARRIVE guidelines (Kilkenny et al., 2010, 
McGrath et al., 2010). 
 
Acute myocardial infarction model 
Myocardial infarction was induced as previously reported (Karwi et al., 2016). Briefly, rats 
were anaesthetised using thiobutabarbital (Inactin® 200 mg kg-1, i.p) and anaesthesia was 
maintained throughout the procedure by supplemental dosing (75 mg kg-1, i.v) as required. 
The left jugular vein was cannulated for drug administration while the right common carotid 
artery was cannulated and connected to a pressure transducer (Powerlab data acquisition 
system, AD instruments, Abingdon, UK) to monitor the heart rate and the blood pressure 
throughout the experiment. The trachea was intubated and the animal ventilated with room air 
using a small animal ventilator (Hugo Sachs Elektronik, March, Germany) at a rate of 75 
strokes min-1 and tidal volume of 1.0 to 1.25 mL 100 g-1. The chest was opened by midline 
sternotomy and the heart exposed using a retractor. The pericardium was incised and a 4/0 
braided silk suture (Mersilk, Ethicon Ltd, UK) was placed around the left main coronary 
artery close to its origin to induce regional ischaemia. Electrocardiography (ECG) was 
monitored using standard lead lI electrodes inserted subcutaneously into the limbs and 
connected to a Powerlab data acquisition system. Rectal temperature was maintained at 37 ± 
1 °C using thermal blanket (Harvard Apparatus Ltd, Cambridge, UK).The following 
inclusion criteria were employed during the stabilisation period of 20 minutes: no ECG or 
visual signs of ischaemia, steady sinus rhythm without arrhythmia, heart rate ≥ 250 beats per 
minute, diastolic blood pressure ≥ 50 mmHg. 
 
To induce regional ischaemia in the left ventricle, the left coronary artery was transiently 
occluded for 30 minutes by pulling the ligature taut through a plastic snare fixed against the 
epicardium. Ischaemia was confirmed by colour change of the left ventricle, drop in the mean 
arterial pressure (MAP), ST-segment elevation and arrhythmia developing between 5-13 
minutes of ischaemia. The ligature was then released to start reperfusion for 120 minutes. 
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Successful reperfusion was confirmed by blushing of the previously ischaemic area, 
reperfusion-induced arrhythmia and increase in the MAP. 
Infarct size determination 
At the end of 120 minutes reperfusion, the heart was harvested and retrograde perfused with 
saline through the aorta on a modified Langendorff apparatus. The ligature was re-occluded 
and the heart perfused with 2% Evans’ blue dye to delineate the ischaemic area at risk 
(AAR), then quickly frozen at -20°C for 24 hours. The heart was transversely sectioned into 
5-6 sections of 2 mm thickness and incubated with 1% w/v triphenyltetrazolium chloride 
(TTC) for 15 minutes. Sections were then fixed with 4% formalin in PBS for 24 hours before 
being scanned. Sections were scanned using digital scanner and coded using random number 
generator (https://www.random.org) then planimetry was carried out in blind fashion using 
the image analysis program Image J (version 1.47, NIH, Bethesda, USA). The analysis 
determined the total ventricular area (TVA, Evans’ blue positive), area at risk (AAR, TTC 
positive) and the infarcted area (I, TTC negative), which were converted to volumes by 
multiplying these areas by 2 mm section thickness. Infarct size was expressed as a percentage 
of the area at risk (% I/AAR).  
 
Treatment protocols 
Experimental protocols are summarised in Figure 1. Two series of experiments were carried 
out. The first series characterised the dose-dependent infarct-limiting effect of AP39 along 
with AP219 (mitochondria-targeting moiety) and ADT-OH (H2S-releasing moiety) to 
confirm the selective effect of H2S delivery into the mitochondria. Doses of AP39, AP219 
and ADT-OH used in these experiments derived from in vitro and in vivo studies undertaken 
by others (Szczesny et al., 2014, Ikeda et al., 2015, Ahmad et al., 2016). 
 
Animals were randomised to receive one of six interventions (Figure 1A):  Group 1: Control (n=10). Animals received a bolus dose of (0.05% DMSO, i.v.) 10 
min before reperfusion. DMSO was used as a vehicle for AP39, AP219 and ADT-OH.  Group 2-4: Each group (n=8) received AP39 at (0.01, 0.1 or 1 µmol kg-1, 
respectively) as an i.v. bolus 10 min before reperfusion.  Group 5: AP219 (n=8). Animals received AP219 (1 µmol kg-1) as an i.v. bolus 10 min 
before reperfusion. 
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 Group 6: ADT-OH (n=8). Animals received ADT-OH (1 µmol kg-1) as an i.v. bolus 
10 min before reperfusion. 
 
The optimum dose of AP39 (1 µmol kg-1), selected from the first series of experiments, was 
used in a second series of experiments which investigated the involvement of the RISK 
pathway components using inhibitors of Akt phosphorylation (LY294002), eNOS (L-NAME) 
or soluble guanylyl cyclase (ODQ). Animals were randomly assigned to one of the following 
eight treatment groups (Figure 1B). 
  Group 1: Control (n=11). Animals received DMSO 0.05% given as an i.v. bolus 15 
min before reperfusion. DMSO was used as vehicle for AP39, LY294002 and ODQ.  Group 2: AP39 (n=8). Animals received AP39 (1 µmol kg-1) as an i.v. bolus 10 min 
before reperfusion.  Group 3: AP39 + L-NAME (n=8). L-NAME (20 mg kg-1) was administered 15 min 
before reperfusion as an i.v. bolus followed by AP39 (1 µmol kg-1) 10 min before 
reperfusion.  Group 4: L-NAME (n=8). L-NAME (20 mg kg-1) was administered 15 min before 
reperfusion as an i.v. bolus.  Group 5: AP39 + LY294002 (n=8). LY294002 (0.3 mg kg-1) was given 15 min before 
reperfusion as an i.v. bolus followed by AP39 (1 µmol kg-1) 10 min before 
reperfusion.  Group 6: LY294002 (n=8). LY294002 (0.3 mg kg-1) was administered 15 min before 
reperfusion as an i.v. bolus.  Group 7: AP39 + ODQ (n=8). ODQ (1 mg kg-1) was given 15 min before reperfusion 
as an i.v. bolus followed by AP39 (1 µmol kg-1) 10 min before reperfusion.  Group 8: ODQ (n=8). ODQ (1 mg kg-1) was administered 15 min before reperfusion 
as an i.v. bolus. 
 
In a parallel series prepared for biochemical analysis of RISK pathway components, animals 
were randomised to receive either vehicle (0.05% DMSO) or AP39 (1 µmol kg-1) 10 minutes 
before reperfusion (Figure 1C). The heart was excised after 5 min of reperfusion and washed 
with saline to remove any blood residue. Tissue samples were rapidly harvested from the left 
ventricle, snap frozen with liquid nitrogen then kept at −80 ºC. These samples were used to 
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investigate the effect of AP39 on the phosphorylation of Akt, eNOS, GSK-3β and ERK1/2 at 
the commencement of reperfusion using Western blotting. 
 
Isolation of cardiac mitochondria 
Isolation of two mitochondrial subpopulations, subsarcolemmal mitochondria (SSM) and 
interfibrillar mitochondria (IFM), was carried out using a modified protocol after Boengler et 
al. (2009). All the procedures were undertaken at 4 ºC to maintain mitochondrial integrity. 
Each rat was anaesthetised with 4% v/v isoflurane and the heart was quickly excised and 
washed with Buffer A (100 mM KCl, 50 mM 3-[N-morpholino]-propanesulfonic acid 
(MOPS), 5 mM MgSO4, 1 mM ATP, 1 mM EGTA, pH 7.4). The ventricles were isolated and 
weighed. Ventricles were transferred to Buffer B (Buffer A + 0.04% bovine serum albumin), 
finely chopped with scissors then gently minced with 6 strokes of a teflon pestle in a glass 
tube. Homogenate was centrifuged at 800 g for 10 min. The supernatant from the first 
centrifugation was collected and centrifuged for 10 minutes at 8000 g to isolate the SSM. The 
sediment was resuspended for 1 minute in Buffer B with protease nargase (8 U g-1) then 
gently minced with 5 strokes of teflon pestle and glass mortar. The homogenate was 
centrifuged at 800 g for 10 minutes then the supernatant was collected and centrifuged for 10 
minutes at 8000 g to sediment the IFM. SSM and IFM were washed with buffer A and final 
pellets were resuspended in Buffer A with no ATP. Protein concentration was determined 
using Lowry assay (BioRad, Hercules, Canada). 
 
Calcium retention capacity (CRC) 
Mitochondrial tolerance to calcium overload, a trigger to PTP opening, was investigated in 
the presence and absence of AP39 using a modified protocol of Chen et al. (2012). Freshly 
isolated SSM and IFM (0.1mg mL-1) were randomised to be incubated for 4 minutes in 2 mL 
(in mM: KCl 125, Tris-MOPS 10, KH2PO4 1.2, MgCl2 1.2, glutamate 5, malate 2.5). The 
suspension was supplemented with 8 µL ADP (10 mM), 10 µL EGTA (1 mM), 6 µL CaCl2 
(5 mM) and calcium green-5N (1 µM, Invitrogen, Carlsbad, Canada). Mitochondria were 
treated with vehicle (0.003% ethanol) or AP39 (1 µM) during the incubation period. 
Cyclosporine A (1 µM) was used as a positive control as it is a well-known inhibitor of the 
PTP opening and increases mitochondrial tolerance to Ca2+ overload in a cyclophilin D-
dependent mechanism. Pulses of Ca2+ (5 µmol) were added at 3 minutes intervals to the 
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solution with stirring at 25 ºC and mitochondrial calcium tolerance was expressed as µmol of 
Ca2+ mg-1 of protein. Fluorescence was measured with excitation and emission wavelengths 
530 and 530 nm, respectively. Data were coded using random number generator 
(https://www.random.org) and blindly analysed.  
 
Mitochondrial oxygen consumption 
The respiration of SSM and IFM was measured using a Clark-type oxygen electrode 
(Strathkelvin, Glasgow, UK) at 25 ºC. The concentrations range of AP39 used for the 
mitochondrial studies were equivalent to the in vivo doses and after assessing the direct effect 
of AP39 on the mitochondria autoflouresence and membrane potential (data not shown). 
Basal mitochondrial oxygen consumption was measured in the presence and absence of either 
the vehicle (0.003% ethanol) or AP39 (0.3, 1, 3, 5 µM). Mitochondria (0.1 mg ml-1) were 
randomised to receive one of the treatments and were incubated in two chambers 
simultaneously, one with complex I substrate (5 mM glutamate and 2.5 mM malate) or with 
complex II substrate (5 mM succinate plus 2 µM of rotenone, to inhibit complex I activity). 
Respiration was stimulated by addition of 40 µM of ADP and oxygen consumption was 
reported as nmol of O2/min/mg of protein. Oxygraph charts were randomly coded 
(https://www.random.org) and blindly analysed. 
 
Mitochondrial ROS (mito-ROS) generation 
Measurement of mito-ROS generation was carried out as previously descripted by Soetkamp 
et al. (2014). Freshly isolated SSM or IFM (50 µg) were suspended in incubation buffer (in 
mM: Tris-MOPS 10, EGTA 0.02, KCl 125, glutamate 5, malate 2.5, Pi-Tris 1.2, MgCl2 1.2, 
pH 7.4). 0.1 U mL-1 horseradish peroxidase (HRP, Roche Diagnostic, Grenzach, Germany) 
and fifty µmol Amplex UltraRed (Invitogen, Eugene, OR) was added to the suspension 
directly before the measurement. Cardiomyocyte mitochondria were randomly incubated 
with: 1) no intervention, (2) vehicle (0.003% ethanol), (3) AP39 (0.3, 1, 3 and 5 µM). A 
second control group with no intervention was employed at the end of the all measurements 
to ensure that any observed effects are due to AP39 and not because of the decline in the 
respiratory capacity. SSM and IFM were also incubated with Rotenone (2 µM) to induce 
overproduction of mito-ROS generation and used as a positive control. Mito-ROS generation 
was measured for 4 minutes at room temperature using Cary Eclipse spectrophotometer 
(Agilent technologies, Santa Clara, Canada) at excitation/emission wavelengths 565/581 nm. 
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Using code generator (https://www.random.org), data were coded and the slope of mito-ROS 
generation was calculated, as a mean fluorescence per time (a.u.), by an operator blind to the 
treatments after subtracting the background fluorescence of the incubation buffer.  
 
Western blot analysis 
Myocardial samples were homogenised and lysed using a hard tissue lysing kit (Stretton 
Scientific Ltd, Stretton, UK). Thirty µg of protein was loaded into each well of 10% w/v 
sodium dodecyl sulfate-polyacylamide gel and separated electrophoretically at (120 mV). 
Separated proteins were transferred onto nitrocellulose membrane (Amersham, Germany) and 
the membrane was blocked for non-specific binding with 5% skimmed milk for 2 hours. The 
membrane was then probed with the primary antibody overnight at 4 ºC. The membrane was 
then incubated with secondary antibody (goat anti-rabbit HRP, 1:15000, Cell Signalling UK) 
for 1 hour at room temperature. Super Signal West Dura Extended Duration Substrate 
(Thermo Scientific, UK) was added on the surface of the membrane to laminate the bands 
and the bands were visualised on X-ray film. Films were scanned and coded and 
densitometry was carried out in blind fashion using Image J software (1.48v, National 
Institutes of Health USA). All protein bands were expressed as the relative density of 
myocardium sample, harvested after 20 minutes of stabilisation (baseline), and then 
normalized for correspondent GAPDH bands which served as an internal standard. 
 
Antibodies 
The following antibodies were used for western blotting: Akt (1:1000), phospho- ser473Akt 
(1:1000), endothelial nitric oxide synthase (eNOS 1:500), phospho- ser1177eNOS (1:500), 
glycogen-synthase kinase-3 beta (GSK-3β 1:1000), phospho- ser9GSK-3β (1:1000), 
extracellular signal-regulated kinases ERK 1/2 (1:1000), phospho- Thr202/Tyr204 ERK 1/2 
(1:1000) and GAPDH (1:50000).  
 
Statistical analysis 
The data and statistical analysis comply with the recommendations on experimental design 
and analysis in pharmacology (Curtis et al., 2015). All data passed the Kolmogorov-Smirnov 
normality test of distribution. Statistical analysis was performed using GraphPad Prism® 
software (2007, Version 5.01, USA) and data presented as mean ± SEM. Infarct size data 
were analysed using one-way ANOVA with Newman-Keuls post hoc test and Western blot 
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analysis was performed using unpaired student’s t test. Haemodynamic and mitochondrial 
data were statistically analysed using repeated measures ANOVA supported by Bonferroni’s 
post hoc test. P<0.05 was considered statistically significant. Post tests were only carried out 
if P<0.05 was achieved in the ANOVA. 
 
Results 
 
For the AP39 dose-response study, 52 rats were used, of which two were excluded: one did 
not have successful reperfusion and one rat did not survive ischaemia-induced ventricular 
fibrillation. Therefore, data from 50 successfully completed experiments are presented. In the 
second series, 83 rats were used, of which four were excluded: two did not complete the 
ischaemia-reperfusion protocol, one did not have successful TTC staining and one did not 
survive reperfusion-induced arrhythmia. Thus, data from 79 rats, 67 infarct size experiments 
which were successfully completed and 12 tissue sampling experiments, were reported. For 
mitochondria functional studies, data from 20 rats are reported. 
 
Pharmacological postconditioning with AP39 
Baseline parameters for infarct size studies are shown in (Table 1). There was no difference 
among the 14 experimental groups in any of the baseline parameters. Risk zone was similar 
among the experimental groups (50-60% of the total ventricular volume, Figure 2A). 
Administration of AP39 10 minutes before reperfusion resulted in a dose-dependent infarct-
sparing effect compared with vehicle-treated animals (Figure 2B). The maximum 
cardioprotection was seen at 1 µmol kg-1 dose with almost 40% reduction in infarct size 
compare to vehicle-treated animals. Postconditioning with AP39 (1 µmol kg-1) also dose-
dependently increased in the post-ischaemic functional recovery (% RPP recovery as a 
percentage of pre-ischaemia RPP) measured at the end of reperfusion (67.2 ± 3.8%) compare 
to the control hearts (46.2 ± 3.8%, Table 1). The control compounds, namely AP219 and 
ADT-OH, did not have a significant effect on either RPP recovery or infarct size, confirming 
that selective delivery of H2S to the mitochondria mediates AP39’s cardioprotection. 
 
Cytosol-independent mechanism of postconditioning with AP39 
We next investigated the effect of AP39 on the RISK pathway as a relevant protective 
cytosolic-signalling pathway using a “signal tracing” technique. Specific pharmacological 
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inhibitors, namely the PI3K inhibitor LY294002 (Jiang et al., 2007), constitutive NOS 
inhibitor L-NAME (Fradorf et al., 2010) and sGC inhibitor ODQ (Routhu et al., 2010) were 
used at doses that have previously been reported to abrogate the activity of their targets in in 
vivo models. 
 
There was no significant difference in either the baseline characteristics or the risk zone 
(ischaemic bed) among the groups (Figure 3A). None of the pharmacological inhibitors had a 
significant effect on infarct size when given alone 15 minutes before reperfusion compared to 
the control group (Figure 3B). Blockade of PI3K activity with LY294002 did not abolish the 
infarct limitation by AP39. Similarly, neither blockade of NO synthesis by L-NAME nor 
selective inhibition of its downstream effector, sGC, with ODQ attenuated the protective 
effect of AP39. 
 
The effect of AP39, used as an adjunct to reperfusion, on the key cytosolic components of the 
RISK pathway was also evaluated in samples harvested from the left ventricle after 5 minutes 
of reperfusion (Figure 4). Immunoblotting was carried out using phospho-specific antibodies 
for Akt, eNOS, GSK-3β and ERK1/2 to outline their role in the cardioprotection. In line with 
the infarct size data, Western blot analysis showed that administration of AP39 at reperfusion 
had no significant effect on the phosphorylation of either Akt, eNOS, GSK-3β or ERK1/2. 
This confirms that AP39 mediated its cardioprotection independently of these cytosolic 
components on the RISK pathway. 
 
Mitochondrial effects of AP39 
We examined the effect of specific-delivery of H2S into the mitochondria on the 
susceptibility to PTP opening. We used freshly isolated SSM and IFM and treated them with 
vehicle or AP39 (1 µM). SSM and IFM were exposed to pulses of Ca2+ in the presence and 
absence of CsA as a positive control (Figure 5). Untreated IFM showed 30% higher calcium 
tolerance (by 30%) than untreated SSM. AP39 elicited a significant inhibitory effect on the 
PTP opening in both SSM and IFM, which represents 30% increase in Ca2+ overload 
tolerance, compared to vehicle-treated mitochondria. The inhibitory effect of AP39 on PTP 
opening was comparable to that observed after CsA in SSM and IFM. Interestingly, AP39 
showed 25% additive effect to CsA-induced inhibition of PTP opening when either SSM or 
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IFM were incubated with both AP39 and CSA before the exposure to Ca2+ pulses, compared 
to CsA alone. 
Mitochondrial respiration was measured for both SSM and IFM using substrates for complex 
I (glutamate and malate) and complex II (succinate, in the presence of rotenone to inhibit 
complex I). There was no difference in the basal respiration of the two subpopulations of 
mitochondria. ADP-stimulated respiration was higher in IFM (by 25% and 31% for complex 
I and II, respectively) compared to SSM. Different concentrations of AP39 (0.3, 1, 3, 5 µM) 
were tested on SSM or IFM; however, none of the concentrations examined significantly 
influenced mitochondrial oxygen consumption. 
 
Overwhelming mito-ROS generation at early reperfusion is one of the main determinants of 
cellular injury. Therefore, we performed in vitro experiments to look at the direct effect of 
AP39 on H2O2 generation in the isolated rat left ventricle mitochondria (Figure 7A, B, C, D). 
In the control groups, ROS generation was significantly lower by 20% in IFM than SSM. 
AP39 showed a dose-dependent inhibition of ROS generation in both SSM and IFM. AP39 (1 
µM) exerted the maximum inhibitory effect (38% in SSM and 61% in IFM) compared to 
control, vehicle-treated and the second control mitochondria. Interestingly, the inhibitory 
effect of AP39 on mito-ROS generation was gradually reduced as the concentration was 
increased. Rotenone, as a positive control, resulted in overproduction of ROS in both SSM 
and IFM by 65% and 75%, respectively, compare the basal ROS generation level. 
 
Discussion 
 
The lipophilic TPP+ scaffold is an attractive moiety for investigating mitochondrial function 
as it selectively accumulates (100-500 fold versus cytosol) in the mitochondrial matrix 
(Murphy and Smith, 2007, Smith et al., 2011). Previous work (Prime et al., 2009) 
demonstrated infarct limitation using a mitochondria-targeted NO donor (MitoSNO) with an 
NO-releasing moiety linked to TPP+. Work by Krieg’s group (Methner et al., 2013) showed 
that MitoSNO works independently of cytosolic protein kinase G which mediates the 
cardioprotective effect of non-mitochondrial-targeted NO donors. AP39 represents the first 
successful attempt to deliver H2S selectively and at low concentration to the mitochondria 
(Le Trionnaire et al., 2014, Tomasova et al., 2014, Szczesny et al., 2014, Ikeda et al., 2015, 
Ahmad et al., 2016).  
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In the present study, AP39 significantly limited infarct size (Figure 2B) and improved the 
post-ischaemic functional recovery (Table 1), both in a dose-dependent manner, when 
administered prior to reperfusion. Consistent with these data, Ahmed et al. (2016) reported 
that AP39 also exerted attenuation in renal damage, oxidative stress and renal inflammation 
when applied at reperfusion in an in vivo renal ischaemia-reperfusion injury model. We 
observed that the TPP+ scaffold molecule (AP219) and the H2S-generating moiety (ADT-
OH), which were used as controls, had no effect on myocardial injury. This is in agreement 
with other reports where these controls lacked biologically activity when used at nanomolar 
or micromolar concentrations (Le Trionnaire et al., 2014, Szczesny et al., 2014, Ahmad et al., 
2016).  
 
At the time of finalising this manuscript, recent work with AP39 by Papapetropoulos’s group 
(Chatzianastasiou et al., 2016) has appeared. The main focus of Chatzianastasiou’s work is 
“head-to-head” comparison of infarct limitation by different H2S donors (Na2S, GYY4137, 
thiovaline and AP39), and elucidation of the role of NO in mediating protection. Intriguingly, 
all donors had the same infarct-limiting effect in a mouse model of ischaemia-reperfusion 
injury. It is noteworthy that the optimum cardioprotective doses of GYY4137 and AP39 used 
were 26.6 µmole kg-1 and 0.25 µmol kg-1, respectively. Very recently, we reported that 26.6 
µmole kg-1 GYY4137 was not cardioprotective in an in vivo rat model of ischaemia-
reperfusion injury with the optimum cardioprotective dose being 10-fold higher (Karwi et al., 
2016). Similarly, in the present study we demonstrated that AP39 exerts an infarct-sparing 
effect with an optimum cardioprotective dose of 1 µmol kg-1, 4-fold higher than the effective 
dose in mouse reported by Chatzianastasiou et al. (2016). No haemodynamic data are 
available to compare AP39-induced dose-dependent improvement in post-ischaemic 
functional recovery with Chatzianastasiou’s paper.  
 
Our present study provides important mechanistic insight into AP39’s cardioprotective action 
in vivo. We found that selective blockade of PI3K, which is known to mediate the 
cardioprotective effect of non-mitochondrial H2S donors (Andreadou et al., 2015, Karwi et 
al., 2016), did not abolish cardioprotection (Figure 3B). Cross-talk/interaction between H2S 
and NO has different patterns depending on organs/tissues, experimental conditions and 
species (Karwi et al., 2016, Bibli et al., 2015, King et al., 2014). To test if NO/sGC pathway 
mediates the effect of AP39, we blocked the endogenous NO synthesis pathway and also 
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inhibited the activity of its end effector (sGC) using L-NAME and ODQ, respectively. We 
found that cardioprotection by AP39 was still observed in the presence of L-NAME or ODQ, 
supported by analysis of protein phosphorylation during early reperfusion. We observed that 
AP39 did not induce phosphorylation of Akt, eNOS, GSK-3β, a downstream effector of the 
RISK pathway, or ERK1/2, a parallel arm of the RISK pathway at 5 min reperfusion (Figure 
4A, B, C and D). Chatzianastasiou et al. (2016) reported that AP39 did not phosphorylate 
either eNOS ser1176 or VASP ser239 after 10 minutes of reperfusion and its cardioprotection 
was not abolished by either L-NAME or DT2, indicating a cGMP/PKG-independent 
mechanism in the murine model. Their data are complementary to the fuller characterisation 
of the potential cytosolic signalling targets of AP39 that we present here. Viewed together, 
our data and those of Chatzianastasiou et al. (2016) provide persuasive evidence that, unlike 
other H2S donors, AP39 mediates its cardioprotection by a mechanism that is independent of 
activation of the cytosolic components of the RISK signalling cascade. 
 
Intra-mitochondrial H2S is essential for normal function of the citric acid cycle. Levels are 
disturbed during oxidative stress due to increased H2S degradation and reduced production 
(Geng et al., 2004, Doeller et al., 2005, Whiteman et al., 2011, Vandiver and Snyder, 2012). 
H2S supplements or overexpression of endogenous synthetic enzymes have been shown to 
protect against ischaemia-reperfusion injury by mitigating oxidative stress and preserving 
mitochondrial integrity (Andreadou et al., 2015). Interestingly, Kai et al. (2012) found that 
NaHS-induced protection was abolished in mitochondria-free cells. Nevertheless, whether 
H2S directly interacts with mitochondria or triggers cytosolic signalling pathways that 
converge on the mitochondria may depend on the intracellular level of H2S. Therefore, we 
have characterised for the first time the direct effect of AP39 on the most relevant 
subpopulations of cardiomyocyte mitochondria, namely subsarcolemmal (SSM) and 
interfibrillar (IFM) mitochondria. Inhibition of the PTP opening in the first minutes of 
reperfusion has been extensively reported to protect against reperfusion injury (Halestrap, 
2010, Ong et al., 2014). It has been shown that many cardioprotective interventions act to 
maintain PTP in a closed state (Hausenloy et al., 2009). With this in mind, we investigated 
the influence of AP39 on the opening of PTP, as a result of Ca2+ overload, in cardiac SSM 
and IFM. We found that AP39 inhibited PTP opening in SSM and IFM (Figure 5) with no 
significant difference from the inhibitory effect of the positive control, CsA, which can 
protect myocardium against ischaemia-reperfusion injury (Hausenloy et al., 2012). We 
observed that AP39 and CsA in combination increased mitochondrial tolerance to Ca2+ 
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overload and resulted in an additive effect compared to either compound alone. CsA prevents 
the opening of PTP by desensitising cyclophilin-D, a component of the multiprotein complex 
spanning the inner and outer mitochondrial membranes, which is a modulator of PTP located 
in the mitochondrial matrix (Bernardi and Di Lisa, 2015). Having an additive effect to CsA 
suggests that AP39 may inhibit PTP opening via a cyclophilin-D independent mechanism. 
Chatzianastasiou et al. (2016) reported that AP39 (0.3 µM versus 1 µM in our study), exerted 
an additive effect to CsA in mouse mitochondria isolated from the whole heart. However, 
isolating mitochondria from whole heart tissue is potentially problematic as a number of cell 
types contribute to the isolated mitochondrial fraction, for example endothelial cells, 
fibroblasts and other local resident cells. Even more important, cardiomyocyte mitochondria, 
namely SSM and IFM, themselves significantly differ in their main characteristics including 
oxygen consumption, mito-ROS generation and calcium retention capacity (Palmer et al., 
1977, Palmer et al., 1986). Our present study confirms for the first time the effect of AP39 in 
specific cardiomyocyte mitochondria and both IFM and SSM subpopulations.  
 
It has been reported that H2S can stimulate mitochondrial ATP production by acting as an 
electron donor for the electron transport chain (Szabo et al., 2014, Modis et al., 2014). 
Accordingly, we explored the influence of AP39 on mitochondrial respiration through 
complexes I and II in both SSM and IFM. The respiration control ratio (RCR), an index for 
the coupling between mitochondrial respiration and oxidative phosphorylation, for isolated 
mitochondria fractions in this study was around (2.5). Although this result is comparable to 
our previously data (Boengler et al. 2009), others have reported higher RCR ratios (Chen et 
al., 2008; Asemu et al., 2013; Gao et al., 2013). This could be due to either measuring oxygen 
consumption at 30 ºC instead of 25 ºC, using trypsin instead of nargase to release the 
interfibrillar mitochondria or stimulating the mitochondria with higher concentration of ADP 
than what was used in this study. We did not detect any significant effect of AP39 on the 
oxygen consumption of these complexes in either mitochondrial subpopulation (Figure 6). 
These data suggest the safety margin of the applied concentration range. More importantly 
and in line with others, these results show that electron supply by H2S (at low concentration) 
to the electron transport chain occurs at the level of coenzyme Q where sulfide quinone 
reductase (SQR) activity is involved. Following that, electrons will flow forward toward 
Complex III and Complex IV without affecting either Complexes I or II (Goubern et al., 
2007; Szabo et al., 2014). It has been demonstrated that inhibition of Complex I using 
rotenone did not affect sulfide oxidation while inhibition of Complex III or VI by antimycin 
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or cyanide, respectively, impeded it (Goubern et al., 2007; Volkel & Grieshaber, 1996; Yong 
& Searcy, 2001). Investigating the effect of AP39 on mitochondrial respiration at 37 °C also 
needs further investigation in future work.  
 
The detrimental effect of overwhelming mito-ROS generation, as a result of respiratory chain 
uncoupling, is one of the hallmarks of ischaemia-reperfusion injury (Brown and Griendling, 
2015, Venditti et al., 2001). It is a major contributor to the opening of PTP, initiating cell 
apoptosis and accelerated necrosis during reperfusion (Hausenloy et al., 2009). Since 
oxidative stress and the mitochondria play central roles in ischaemia-reperfusion injury, 
targeting the mitochondria with selective H2S donors is a plausible therapeutic approach to 
limit ischaemia-reperfusion injury. Here, we have investigated for the first time the influence 
of AP39 on mito-ROS generation in both SSM and IFM. We found that AP39 limited mito-
ROS level in both subpopulations (Figure 7) which is in line with other studies of mito-ROS 
reduction with AP39 (Szczesny et al., 2014, Le Trionnaire et al., 2014, Ikeda et al., 2015, 
Ahmad et al., 2016). We also observed an attenuation in AP39’s activity as its concentration 
was increased, consistent with the findings of others (Szczesny et al., 2014, Ahmad et al., 
2016).  
 
Although we have provided novel mechanistic insights into how AP39 could mediate 
cardioprotection, there are several caveats and current limitations. Assessing the extent of 
mitochondrial H2S level increase following AP39 application remains a challenge due to the 
lack of sensitive probes. Ikeda et al. (2015) reported that AP39 did not influence the 
expression of CSE, CBS or 3-MST in the brain. This suggests that AP39 probably elevates 
mitochondrial H2S level without interfering with the endogenous synthesis of H2S. The focus 
of ongoing work is to investigate whether AP39 supresses oxidative stress by increasing GSH 
production or by upregulating mito-ROS scavenging pathways or by directly scavenging 
ROS. The exact mechanism/target whereby AP39 inhibits PTP opening also remains to be 
determined. It may be interesting to identify what happens to these subpopulations in the 
animal treated with AP39. Both subpopulations play significant roles in mediating 
cardioprotection, although it is possible this includes persulfidation (also called S-
sulfhydration) of mitochondrial proteins such as ATP synthase (Modis et al., 2016; Wedmann 
et al., 2016). Very recent work by Murphy’s group (Sun, Aponte, Menazza, Gucek, 
Steenbergen & Murphy, 2016) also proposed that postconditioning with NaHS protected 
against myocardial infarction via an increase in S-nitrosylation and most of the S-nitrosylated 
 This article is protected by copyright. All rights reserved. 
proteins were mitochondrial proteins. This further emphasises the physiological importance 
of post-translation modifications of H2S and its interaction with NO in the mitochondria, a 
phenomenon that we are now seeking to characterise. 
 
In conclusion, our results confirm that AP39 can protect the heart against myocardial 
infarction when given at reperfusion in a manner that is independent of classical cytosolic 
signalling mechanisms. We also report for the first time that AP39 inhibits mito-ROS 
generation and PTP opening in both SSM and IFM, probably in a cyclophilin D-independent 
manner without affecting mitochondrial respiration. These findings provide proof-of-concept 
that direct delivery of H2S to mitochondria by mitochondria-targeting H2S donors, of which 
AP39 is a prototype of several compounds in this class under development, represents a novel 
and effective adjunctive intervention to mitigate the irreversible myocardial injury associated 
with reperfusion. 
 
Author contributions 
QGK and GFB conceived and designed the studies and wrote the first draft of the manuscript. 
QK performed all the in vivo studies, biochemical studies and mitochondrial studies. JB, KB 
and RS designed the mitochondrial studies and assisted QK with performing mitochondrial 
experiments and analysis of mitochondrial function data. MEW, RT and MW designed, 
synthesised and characterised AP39 and related compounds. All authors contributed to 
revision of the manuscript prior to finalisation for submission by QK and GFB. 
 
Acknowledgements  
QK acknowledges the generous support of the Iraqi Ministry of Higher Education and 
Scientific Research. RT is the recipient of The Brian Ridge Scholarship. MW and MEW 
would like to thank the Medical Research Council (UK) MR/M022706/1 for their generous 
support. Authors also thank Elvira Ungefug, Anna Reis, Sabrina Bohme and Christine 
Hirschhauser for their support. 
  
 This article is protected by copyright. All rights reserved. 
Conflicts of interest 
MW, MEW and the University of Exeter have intellectual property (patent filings) on AP39, 
related compounds and their use. 
 
Declaration of transparency and scientific rigour 
This declaration acknowledges that this paper adheres to the principles for transparent 
reporting and scientific rigour of preclinical research recommendation by funding agencies, 
publishers and other organizations engaged with supporting research. 
  
 This article is protected by copyright. All rights reserved. 
References 
 
Ahmad A, Olah G, Szczesny B, Wood ME, Whiteman M, & Szabo C (2016). AP39, a 
mitochondrially targeted hydrogen sulfide donor, exerts protective effects in renal epithelial 
cells subjected to oxidative stress in vitro and in acute renal injury in vivo. Shock 45: 88-97. 
 
Alexander SP, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, et al. (2015). The 
Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024-6109. 
 
Andreadou I, Iliodromitis EK, Rassaf T, Schulz R, Papapetropoulos A, & Ferdinandy P 
(2015). The role of gasotransmitters NO, H2S and CO in myocardial ischaemia/reperfusion 
injury and cardioprotection by preconditioning, postconditioning and remote conditioning. Br 
J Pharmacol 172: 1587-1606. 
 
Asemu G, O'Connell KA, Cox JW, Dabkowski ER, Xu W, Ribeiro RF, Jr., Shekar, KC, 
Hecker PA, Rastogi S, Sabbah HN, Hoppel CL, Stanley WC (2013). Enhanced resistance to 
permeability transition in interfibrillar cardiac mitochondria in dogs: effects of aging and 
long-term aldosterone infusion. Am J Physiol Heart Circ 304: H514-H528. 
 
Bernardi P, & Di Lisa F (2015). The mitochondrial permeability transition pore: molecular 
nature and role as a target in cardioprotection. J Mol Cell Cardiol 78: 100-106. 
 
Bibli SI, Andreadou I, Chatzianastasiou A, Tzimas C, Sanoudou D, Kranias E, et al. (2015). 
Cardioprotection by H2S engages a cGMP-dependent protein kinase G/phospholamban 
pathway. Cardiovasc Res 106: 432-442. 
 
Boengler K, Stahlhofen S, van de Sand A, Gres P, Ruiz-Meana M, Garcia-Dorado D, et al. 
(2009). Presence of connexin 43 in subsarcolemmal, but not in interfibrillar cardiomyocyte 
mitochondria. Basic Res Cardio 104: 141-147. 
 
Bos EM, van Goor H, Joles JA, Whiteman M, & Leuvenink HG (2015). Hydrogen sulfide: 
physiological properties and therapeutic potential in ischaemia. Br J Pharmacol 172: 1479-
1493. 
 This article is protected by copyright. All rights reserved. 
Brown DI, & Griendling KK (2015). Regulation of signal transduction by reactive oxygen 
species in the cardiovascular system. Circ Res 116: 531-549. 
 
Chatzianastasiou A, Bibli SI, Andreadou I, Efentakis P, Kaludercic N, Wood ME, et al. 
(2016). Cardioprotection by H2S donors: nitric oxide-dependent and -independent 
mechanisms. J Pharmacol Exp Ther. DOI: 10.1124/jpet.116.235119. 
 
Chen Q, Moghaddas S, Hoppel CL, & Lesnefsky EJ (2008). Ischemic defects in the electron 
transport chain increase the production of reactive oxygen species from isolated rat heart 
mitochondria. Am J Physiol Cell Physiol 294: C460-C466. 
 
Chen Q, Paillard M, Gomez L, Li H, Hu Y, & Lesnefsky EJ (2012). Postconditioning 
modulates ischemia-damaged mitochondria during reperfusion. J Cardiovasc Pharmacol 59: 
101-108. 
 
Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA, et al. (2015). 
Experimental design and analysis and their reporting: new guidance for publication in BJP. 
Br J Pharmacol 172: 3461-3471. 
 
Doeller JE, Isbell TS, Benavides G, Koenitzer J, Patel H, Patel RP, et al. (2005). 
Polarographic measurement of hydrogen sulfide production and consumption by mammalian 
tissues. Anal Biochem 341: 40-51. 
 
Elrod JW, Calvert JW, Morrison J, Doeller JE, Kraus DW, Tao L, et al. (2007). Hydrogen 
sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial 
function. Proc Natl Acad Sci U S A 104: 15560-15565. 
 
Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, & Schulz R (2014). Interaction of risk 
factors, comorbidities, and comedications with ischemia/reperfusion injury and 
cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol 
Rev 66: 1142-1174. 
 
Fradorf J, Huhn R, Weber NC, Ebel D, Wingert N, Preckel B, et al. (2010). Sevoflurane-
induced preconditioning: impact of protocol and aprotinin administration on infarct size and 
 This article is protected by copyright. All rights reserved. 
endothelial nitric-oxide synthase phosphorylation in the rat heart in vivo. Anesthesiology 
113: 1289-1298. 
 
Gao XH, Qanungo S, Pai HV, Starke DW, Steller KM, Fujioka H, Lesnefsky EJ, Kerner J, 
Rosca MG, Hoppel CL, Mieyal JJ (2013). Aging-dependent changes in rat heart 
mitochondrial glutaredoxins--Implications for redox regulation. Redox Biol 1: 586-598. 
 
Geng B, Chang L, Pan C, Qi Y, Zhao J, Pang Y, et al. (2004). Endogenous hydrogen sulfide 
regulation of myocardial injury induced by isoproterenol. Biochem Biophys Res Commun 
318: 756-763. 
 
Goubern M, Andriamihaja M, Nubel T, Blachier F, & Bouillaud F (2007). Sulfide, the first 
inorganic substrate for human cells. FASEB J 21: 1699-1706. 
 
Halestrap AP (2010). A pore way to die: the role of mitochondria in reperfusion injury and 
cardioprotection. Biochem Soc Trans 38: 841-860. 
 
Hausenloy DJ (2013). Cardioprotection techniques: preconditioning, postconditioning and 
remote conditioning (basic science). Curr Pharm Des 19: 4544-4563. 
 
Hausenloy DJ, Boston-Griffiths EA, & Yellon DM (2012). Cyclosporin A and 
cardioprotection: from investigative tool to therapeutic agent. Br J Pharmacol 165: 1235-
1245. 
 
Hausenloy DJ, Ong SB, & Yellon DM (2009). The mitochondrial permeability transition 
pore as a target for preconditioning and postconditioning. Basic Res Cardiol 104: 189-202. 
 
Hausenloy DJ, & Yellon DM (2007). The evolving story of "conditioning" to protect against 
acute myocardial ischaemia-reperfusion injury. Heart 93: 649-651. 
 
Ikeda K, Marutani E, Hirai S, Wood ME, Whiteman M, & Ichinose F (2015). Mitochondria-
targeted hydrogen sulfide donor AP39 improves neurological outcomes after cardiac arrest in 
mice. Nitric oxide 49: 90-96. 
 
 This article is protected by copyright. All rights reserved. 
Jiang R, Zatta A, Kin H, Wang N, Reeves JG, Mykytenko J, et al. (2007). PAR-2 activation 
at the time of reperfusion salvages myocardium via an ERK1/2 pathway in in vivo rat hearts. 
Am J Physiol Heart Circ 293: H2845-H2852. 
 
Johansen D, Ytrehus K, & Baxter GF (2006). Exogenous hydrogen sulfide (H2S) protects 
against regional myocardial ischemia-reperfusion injury--Evidence for a role of K ATP 
channels. Basic Res Cardiol 101: 53-60. 
 
Kai S, Tanaka T, Daijo H, Harada H, Kishimoto S, Suzuki K, et al. (2012). Hydrogen sulfide 
inhibits hypoxia- but not anoxia-induced hypoxia-inducible factor 1 activation in a von 
hippel-lindau- and mitochondria-dependent manner. Antioxid Redox Signal 16: 203-216. 
 
Karwi QG, Whiteman M, Wood ME, Torregrossa R, & Baxter GF (2016). Pharmacological 
postconditioning against myocardial infarction with a slow-releasing hydrogen sulfide donor, 
GYY4137. Pharmacol Res 111: 442-451. 
 
Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, & Group NCRRGW (2010). 
Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 
160: 1577-1579. 
 
Kimura H (2011). Hydrogen sulfide: its production and functions. Exp Physiol 96: 833-835. 
 
King AL, Polhemus DJ, Bhushan S, Otsuka H, Kondo K, Nicholson CK, et al. (2014). 
Hydrogen sulfide cytoprotective signaling is endothelial nitric oxide synthase-nitric oxide 
dependent. Proc Natl Acad Sci U S A 111: 3182-3187. 
 
Le Trionnaire S, Perry A, Szczesny B, Szabo C, Winyard PG, Whatmore JL, et al. (2014). 
The synthesis and functional evaluation of a mitochondria-targeted hydrogen sulfide donor, 
(10-oxo-10-(4-(3-thioxo-3H-1,2-dithiol-5-yl)phenoxy)decyl)triphenylphosphonium bromide 
(AP39). Med Chem Comm 5: 728-736. 
 
McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, & Wainwright CL (2010). 
Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J 
Pharmacol 160: 1573-1576. 
 This article is protected by copyright. All rights reserved. 
Methner C, Lukowski R, Grube K, Loga F, Smith RA, Murphy MP, et al. (2013). Protection 
through postconditioning or a mitochondria-targeted S-nitrosothiol is unaffected by 
cardiomyocyte-selective ablation of protein kinase G. Basic Res Cardiol 108: 337-343. 
 
Modis K, Bos EM, Calzia E, van Goor H, Coletta C, Papapetropoulos A, et al. (2014). 
Regulation of mitochondrial bioenergetic function by hydrogen sulfide. Part II. 
Pathophysiological and therapeutic aspects. Br J Pharmacol 171: 2123-2146. 
 
Modis K, Ju Y, Ahmad A, Untereiner AA, Altaany Z, Wu L, et al. (2016). S-sulfhydration of 
ATP synthase by hydrogen sulfide stimulates mitochondrial bioenergetics. Pharmacol Res 
113: 116-124. 
 
Murphy E, Ardehali H, Balaban RS, DiLisa F, Dorn GW, 2nd, Kitsis RN, et al. (2016). 
Mitochondrial function, biology, and role in disease: a scientific statement from the american 
heart association. Circ Res 118: 1960-1991. 
 
Murphy MP, & Smith RA (2007). Targeting antioxidants to mitochondria by conjugation to 
lipophilic cations. Annu Rev Pharmacol Toxicol 47: 629-656. 
 
Ong SB, Samangouei P, Kalkhoran SB, & Hausenloy DJ (2014). The mitochondrial 
permeability transition pore and its role in myocardial ischemia reperfusion injury. J Mol Cell 
Cardiol 78:23-34. 
 
Palmer JW, Tandler B, & Hoppel CL (1977). Biochemical properties of subsarcolemmal and 
interfibrillar mitochondria isolated from rat cardiac muscle. J Biol Chem 252: 8731-8739. 
 
Palmer JW, Tandler B, & Hoppel CL (1986). Heterogeneous response of subsarcolemmal 
heart mitochondria to calcium. Am J Physiol 250: H741-H748. 
 
Pell VR, Chouchani ET, Frezza C, Murphy MP, & Krieg T (2016). Succinate metabolism: a 
new therapeutic target for myocardial reperfusion injury. Cardiovasc Res 111:134-41 
 
 This article is protected by copyright. All rights reserved. 
Prime TA, Blaikie FH, Evans C, Nadtochiy SM, James AM, Dahm CC, et al. (2009). A 
mitochondria-targeted S-nitrosothiol modulates respiration, nitrosates thiols, and protects 
against ischemia-reperfusion injury. Proc Natl Acad Sci U S A 106: 10764-10769. 
 
Routhu KV, Tsopanoglou NE, & Strande JL (2010). Parstatin (1-26): the putative signal 
peptide of protease-activated receptor 1 confers potent protection from myocardial ischemia-
reperfusion injury. J Pharmacol Exp Ther 332: 898-905. 
 
Smith RA, Hartley RC, & Murphy MP (2011). Mitochondria-targeted small molecule 
therapeutics and probes. Antioxid Redox Signal 15: 3021-3038. 
 
Soetkamp D, Nguyen TT, Menazza S, Hirschhauser C, Hendgen-Cotta UB, Rassaf T, et al. 
(2014). S-nitrosation of mitochondrial connexin 43 regulates mitochondrial function. Basic 
Res Cardiol 109: 433-451. 
 
Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP, et al. (2016). 
The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative 
interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res 44: D1054-
D1068. 
 
Sun J, Aponte AM, Menazza S, Gucek M, Steenbergen C, & Murphy E (2016). Additive 
cardioprotection by pharmacological postconditioning with hydrogen sulfide and nitric oxide 
donors in mouse heart: S-sulfhydration vs. S-nitrosylation. Cardiovasc Res 110: 96-106. 
 
Szabo C, Ransy C, Modis K, Andriamihaja M, Murghes B, Coletta C, et al. (2014). 
Regulation of mitochondrial bioenergetic function by hydrogen sulfide. Part I. Biochemical 
and physiological mechanisms. Br J Pharmacol 171: 2099-2122. 
 
Szczesny B, Modis K, Yanagi K, Coletta C, Le Trionnaire S, Perry A, et al. (2014). AP39, a 
novel mitochondria-targeted hydrogen sulfide donor, stimulates cellular bioenergetics, exerts 
cytoprotective effects and protects against the loss of mitochondrial DNA integrity in 
oxidatively stressed endothelial cells in vitro. Nitric oxide 41: 120-130. 
 
 This article is protected by copyright. All rights reserved. 
Tomasova L, Pavlovicova M, Malekova L, Misak A, Kristek F, Grman M, et al. (2014). 
Effects of AP39, a novel triphenylphosphonium derivatised anethole dithiolethione hydrogen 
sulfide donor, on rat haemodynamic parameters and chloride and calcium Ca3 and RyR2 
channels. Nitric oxide 46:131-44. 
 
Vandiver M, & Snyder SH (2012). Hydrogen sulfide: a gasotransmitter of clinical relevance. 
J Mol Med 90: 255-263. 
 
Venditti P, Masullo P, & Di Meo S (2001). Effects of myocardial ischemia and reperfusion 
on mitochondrial function and susceptibility to oxidative stress. Cell Mol Life Sci 58: 1528-
1537. 
 
Volkel S, & Grieshaber MK (1996). Mitochondrial sulfide oxidation in Arenicola marina. 
Evidence for alternative electron pathways. FEBS 235: 231-237. 
 
Wedmann R, Onderka C, Wei S, Szijártó IA, Miljkovic JL, Mitrovic A, et al. (2016). 
Improved Tag-Switch Method Reveals that Thioredoxin Acts as Depersulfidase and Controls 
the Intracellular Levels of Protein Persulfidation. Chem Sci 7: 3414-3426. 
 
Whiteman M, Le Trionnaire S, Chopra M, Fox B, & Whatmore J (2011). Emerging role of 
hydrogen sulfide in health and disease: critical appraisal of biomarkers and pharmacological 
tools. Clin Sci 121: 459-488. 
 
Yong R, & Searcy DG (2001). Sulfide oxidation coupled to ATP synthesis in chicken liver 
mitochondria. Comp Biochem Physiol B Biochem Mol Biol 129: 129-137. 
 
  
 This article is protected by copyright. All rights reserved. 
Karwi_Table 1 Summary of the baseline parameters and haemodynamic data throughout 
ischaemia-reperfusion protocol
 This article is protected by copyright. All rights reserved. 
Karwi_Table 1 Summary of the baseline parameters and haemodynamic data throughout 
ischaemia-reperfusion protocol
 This article is protected by copyright. All rights reserved. 
Karwi_Table 1 Summary of the baseline parameters and haemodynamic data throughout ischaemia-reperfusion protocol 
 
 
Experimental Protocol n BW (g) Baseline 20 min Ischaemia 120 min Reperfusion 
   HR 
(BPM) 
RPP  
(mmHg 
min-1*103) 
MAP 
(mmHg) 
HR 
(BPM) 
RPP  
(mmHg 
min-1*103) 
MAP 
(mmHg) 
HR  
(BPM) 
RPP  
(mmHg 
min-1*103) 
MAP 
(mmHg) 
Series 1            
Control (0.05% DMSO) 10 342 ± 5 342 ± 10 36.2 ± 2.1 90 ± 6 311 ± 14 26.0 ± 1.9 70 ± 3 257 ± 9 16.7 ± 2.2 55 ± 5 
AP39 0.01 µmol kg-1 8 347 ± 7 351 ± 8 38.4 ± 2.8 92 ± 4 302 ± 10 27.1 ± 2.4 70 ± 5 245 ± 12 17.7 ± 1.8 58 ± 3 
AP39 0.1 µmol kg-1 8 339 ± 5 349 ± 12 40.0 ± 2.0 89 ± 6 299 ± 14 28.7 ± 1.2 68 ± 7 278 ± 8 20.0 ± 1.3 54 ± 5 
AP39 1 µmol kg-1 8 355 ± 5 356 ± 9 38.5 ± 1.5 85 ± 5 303 ± 10 29.4 ± 2.3 67 ± 3 332 ± 10 25.8 ± 1.2* 49 ± 4 
AP219 1 µmol kg-1 8 356 ± 7 341 ± 10 37.8 ± 2.0 87 ± 7 315 ± 9 27.6 ± 1.6 71 ± 5 250 ± 9 16.2 ± 1.5 51 ± 6 
ADT-OH 1 µmol kg-1 8 342 ± 6 355 ± 12 39.4 ± 2.5 90 ± 4 309 ± 11 29.1 ± 2.3 68 ± 4 243 ± 11 17.5 ± 1.8 54 ± 5 
 
           
Series 2            
Control (0.05% DMSO) 11 361 ± 5 352 ± 12 35.5 ± 2.0 87 ± 6 302 ± 12 26.1 ± 1.7 65 ± 4 255 ± 12 15.2 ± 1.8 53 ± 5 
AP39 1 µmol kg-1 8 356 ± 7 346 ± 9 39.6 ± 3.1 92 ± 4 289 ± 10 31.1 ± 2.0 68 ± 5 320 ± 9 28.2 ± 1.5* 54 ± 6 
AP39 1 µmol kg-1 + 
L-NAME 20 mg kg-1 8 365 ± 6 345 ± 11 36.0 ± 1.9 90 ± 7 285 ± 15 29.5 ± 1.8 67 ± 8 314 ± 13 22.4 ± 2.4* 53 ± 5 
L-NAME 20 mg kg-1 8 371 ± 9 343 ± 10 39.3 ± 1.6 89 ± 5 281 ± 12 28.6 ± 2.4 74 ± 5 230 ± 8 14.4 ± 2.1 56 ± 4 
AP39 1 µmol kg-1 + LY294002 
0.3 mg kg-1 8 359 ± 10 350 ± 7 37.4 ± 1.5 86 ± 6 291 ±10 32.0 ± 2.2 70 ± 6 306 ± 10 24.5 ± 1.6* 52 ± 5 
LY294002 0.3 mg kg-1 8 367 ± 9 351 ± 11 42.3 ± 2.5 91 ± 4 305 ± 14 30.2 ± 1.7 69 ± 6 235 ± 12 16.4 ± 2.0 60 ± 7 
AP39 1 µmol kg-1 +  
ODQ 1 mg kg-1 8 365 ± 7 350 ± 11 39.6 ± 1.5 93 ± 5 291 ± 11 31.5 ± 1.6 71 ± 4 329 ± 9 26.3 ± 1.9* 55 ± 5 
ODQ 1 mg kg-1 8 370 ± 8 342 ± 9 40.3 ± 2.5 88 ± 7 300 ± 10 28.6 ± 1.4 66 ± 5 228 ± 15 15.6 ± 2.0 63 ± 4 
 This article is protected by copyright. All rights reserved. 
Animals body weight and haemodynamic parameters for infarct size studies at the end of stabilisation period (baseline), after 20 minutes of ischaemia and at 
the end of reperfusion. n number of animals per group, BW body weight, HR heart rate (beat per minutes BPM), RPP rate pressure product, MAP mean 
arterial pressure. There was no significant difference among experimental group in the baselines or the application of the pharmacological inhibitors on the 
haemodynamics. Values expressed as mean ± SEM. (Two-way ANOVA followed by Bonferroni post hoc test), * p < 0.05 vs control value at the same time 
point 
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Figure 1 Experimental protocols: animals were underwent 30 minutes of ischaemia followed by 2 hours of reperfusion. Infarct size was 
determined using Evans’ blue/TTC staining technique. Infarction was reported as a percentage of the area at risk (I/AAR %). A AP39 dose effect 
on infarct size: Animals were randomly assigned to be treated with either vehicle or AP39 or the controls (AP219 or ADT-OH) at 10 minutes 
before reperfusion. B mechanistic study: rats were randomised to receive the pharmacological inhibitors, namely LY294002, L-NAME and 
ODQ, at 15 minutes before reperfusion with or without AP39 applied at 10 minutes before reperfusion. Control group only received the vehicle 
(0.05% DMSO) 10 minutes before reperfusion. Arrows indicate the time of pharmacological interventions  
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Figure 2 Infarct-limiting effect of AP39 at reperfusion: A area at risk reported as a percentage of the total ventricular volume. B infarct size 
presented as a percentage of the area at risk. Data were analysed using one-way ANOVA with Neuman Keuls post hoc test and presented as 
mean ± SEM, n = 8 for all groups except the control group (0.05% DMSO) where n = 10. The mean of infarct size for each group is represented 
by a filled circle (with error bars) next to the individual values (open circles). * p<0.05 vs control, † p<0.05 versus AP39 0.1 µmol kg-1 
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Figure 3 Effect of pharmacological inhibitors of the RISK pathway on infarct-limitation by AP39: A risk zone measurements of experimental 
groups expressed as a percentage of the total ventricular area. B myocardial infarction data are expressed as a percentage of the risk zone. 
Individual animal data in each group are represented by empty circles while the mean of infarct size is presented by a full circle. Data were 
analysed via one-way ANOVA followed by Newman Keuls post hoc test and reported as mean ± SEM , n = 8 for all groups except the control 
group where n = 11. * p<0.05 versus control.  
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Figure 4 Effect of AP39 on RISK pathway proteins at early reperfusion: representative Western blots and densitometry analysis of A pAktS473, 
total Akt and GAPDH B p-eNOSS1177, total eNOS, GAPDH C p-GSK-3βS9, GSK-3β and GAPDH D p-ERK1/2Thr202/Tyr204, ERK1/2 and 
GAPDH. Specific antibodies were used to assess the effect of AP39 on the phosphorylation of the RISK components in myocardial biopsies 
harvested from the left ventricle at early reperfusion. Histograms show the relative ratio of phosphorylated protein to the total level of protein. 
GAPDH was used as an internal standard for all quantifications. Data were analysed using student’s t test and presented as mean ± SEM, n=6 per 
group 
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Figure 5 Effect of AP39 on mitochondrial permeability transition pore (PTP) opening: SSM and IFM were incubated individually with vehicle 
(0.003% ethanol) or different concentrations of AP39 and subjected to pulses of 5 µM of CaCl2 per 3 minutes at 25 oC until the opening of PTP 
in the presence and absence of cyclosporine A (CsA). Data expressed as mean ± SEM, n=10, * p<0.05 vs SSM + vehicle, # p<0.05 vs SSM + 
vehicle + CSA, † p<0.05 vs IFM + vehicle, † p<0.05 vs IFM + vehicle, $ p<0.05 vs IFM + vehicle + CSA (two-way ANOVA followed by 
Bonferroni post hoc test, n=10) 
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Figure 6 Effect of AP39 on mitochondrial respiration: respiration of complexes I and II were measured at basal level and after ADP-stimulation 
in the presence and absence of the vehicle or different concentrations of AP39 in subsarcolemmal (SSM) and interfibrillar (IFM) mitochondria. 
Data were analysed via two-way ANOVA with Bonferroni post hoc test and reported as mean ± SEM, n=10, * p<0.05 vs basal respiration 
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Figure 7 Effect of AP39 on mitochondrial-ROS generation: mitochondria were incubated with either vehicle (0.05% DMSO) or different 
concentration of AP39. A and C are representative charts for the ROS generation of SSM and IFM, respectively, and error bars were removed 
for clarity. The slope of ROS generation was measured continuously for 4 minutes with the fluorescence indicator Amplex Ultrared both in B 
subsarcolemmal (SSM) and D interfibrillar (IFM) mitochondria. Data were expressed as mean ± SEM, n=10, * p<0.05 vs 1st control, # p<0.05 vs 
2nd control (two-way ANOVA with Bonferroni post hoc test, n=10) 
 
